165 related articles for article (PubMed ID: 20848473)
1. Safety of infliximab in Crohn's disease: a large single-center experience.
Hamzaoglu H; Cooper J; Alsahli M; Falchuk KR; Peppercorn MA; Farrell RJ
Inflamm Bowel Dis; 2010 Dec; 16(12):2109-16. PubMed ID: 20848473
[TBL] [Abstract][Full Text] [Related]
2. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.
Colombel JF; Loftus EV; Tremaine WJ; Egan LJ; Harmsen WS; Schleck CD; Zinsmeister AR; Sandborn WJ
Gastroenterology; 2004 Jan; 126(1):19-31. PubMed ID: 14699483
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for Crohn's disease: the first 500 patients followed up through 2009.
Seminerio JL; Loftus EV; Colombel JF; Thapa P; Sandborn WJ
Dig Dis Sci; 2013 Mar; 58(3):797-806. PubMed ID: 23053885
[TBL] [Abstract][Full Text] [Related]
5. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
Seiderer J; Göke B; Ochsenkühn T
Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Cohen RD
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
[TBL] [Abstract][Full Text] [Related]
7. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
Ljung T; Karlén P; Schmidt D; Hellström PM; Lapidus A; Janczewska I; Sjöqvist U; Löfberg R
Gut; 2004 Jun; 53(6):849-53. PubMed ID: 15138212
[TBL] [Abstract][Full Text] [Related]
8. Safety of infliximab in 10 years of clinical practice.
O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
[TBL] [Abstract][Full Text] [Related]
9. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea].
Choi KD; Song HJ; Kim JS; Jung HC; Song IS
Korean J Gastroenterol; 2005 Jul; 46(1):48-55. PubMed ID: 16030404
[TBL] [Abstract][Full Text] [Related]
11. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
13. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up.
Wenzl HH; Reinisch W; Jahnel J; Stockenhuber F; Tilg H; Kirchgatterer A; Petritsch W
Eur J Gastroenterol Hepatol; 2004 Aug; 16(8):767-73. PubMed ID: 15256978
[TBL] [Abstract][Full Text] [Related]
14. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.
Sample C; Bailey RJ; Todoruk D; Sadowski D; Gramlich L; Milan M; Cherry R; Ma M; Lalor E; McKaigney J; Sherbaniuk R; Matic K; Switzer C; Fedorak RN
Can J Gastroenterol; 2002 Mar; 16(3):165-70. PubMed ID: 11930194
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study.
Choi CH; Song ID; Kim YH; Koo JS; Kim YS; Kim JS; Kim N; Kim ES; Kim JH; Kim JW; Kim TO; Kim HS; Kim HJ; Park YS; Park DI; Park SJ; Song HJ; Shin SJ; Yang SK; Ye BD; Lee KM; Lee BI; Lee SY; Lee CK; Im JP; Jang BI; Jeon TJ; Cho YK; Chang SK; Jeon SR; Jung SA; Jeen YT; Cha JM; Han DS; Kim WH;
Yonsei Med J; 2016 Nov; 57(6):1376-85. PubMed ID: 27593865
[TBL] [Abstract][Full Text] [Related]
17. Infliximab dependency in a national cohort of children with Crohn's disease.
Wewer V; Riis L; Vind I; Husby S; Munkholm P; Paerregaard A
J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):40-5. PubMed ID: 16385252
[TBL] [Abstract][Full Text] [Related]
18. Use of infliximab in pediatric patients with inflammatory bowel disease.
Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE
Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127
[TBL] [Abstract][Full Text] [Related]
19. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
20. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.
de Ridder L; Rings EH; Damen GM; Kneepkens CM; Schweizer JJ; Kokke FT; Benninga MA; Norbruis OF; Hoekstra JH; Gijsbers CF; Escher JC
Inflamm Bowel Dis; 2008 Mar; 14(3):353-8. PubMed ID: 18069674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
